Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) signed an agreement with a leading global preclinical CRO to run ISO 10993‑compliant, GLP biocompatibility studies as part of its clinical development program.

The studies are expected to begin in Q2 2026, follow recent GMP production of clinical material, an FDA pre‑submission meeting, and positive preclinical allergen‑blocking data, supporting a potential start of clinical trials later in 2026.

Positive

• Preclinical biocompatibility studies to start in Q2 2026
• Studies conducted to ISO 10993 standards under GLP
• Completed GMP production of clinical trial material
• Completed FDA pre‑submission meeting
• Reported positive preclinical allergen‑blocking data
• Clinical trials planned to commence later in 2026

Negative

• None.

News Market Reaction – PLRZ

-4.23%

2 alerts

-4.23% Session close to close

-4.8% Trough Tracked

$23.91M Market Cap

0.1x Rel. Volume

In the Mar 17 session, PLRZ declined 4.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Polyrizon’s progression toward first-in-human studies by engaging a glo...

Analysis

This announcement highlights Polyrizon’s progression toward first-in-human studies by engaging a global CRO to run ISO 10993-compliant biocompatibility studies starting in Q2 2026. The work follows prior milestones such as GMP manufacturing of clinical trial material and positive allergen‑blocking preclinical data. Together, these steps support the planned initiation of clinical trials later in 2026. Investors may watch for completion of the GLP biocompatibility package, regulatory feedback, and how the company funds development under its existing shelf capacity.

Key Figures

Biocompatibility standard: ISO 10993 Study start timing: Q2 2026

2 metrics

Biocompatibility standard ISO 10993 Standard for planned preclinical biocompatibility studies

Study start timing Q2 2026 Preclinical biocompatibility studies expected commencement

Previous Clinical trial Reports

5 past events · Latest: Mar 10 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	GMP CTM manufacturing	Positive	-0.1%	Announced successful GMP batch of clinical trial material for U.S. study.
Jan 05	Preclinical allergen data	Positive	-0.8%	Reported PL-14 significantly reduced Der p 1 transfer vs HPMC comparator.
Oct 06	Allergen-blocking efficacy	Positive	+4.6%	Shared positive PL-14 allergen penetration data supporting clinical plans.
May 21	Hydrogel platform data	Positive	+3.9%	Reported strong mucoadhesion and nasal coverage for intranasal hydrogel platform.
May 13	Epilepsy preclinical start	Positive	-91.9%	Initiated preclinical BZD studies targeting $3.15B acute seizures market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical/preclinical headlines have often shown mixed reactions, with 3 divergences and 2 alignments between positive news and price moves.

Recent Company History

Over the past several months, Polyrizon has steadily advanced its intranasal platform through preclinical milestones and clinical-enabling steps. Events include positive allergen‑blocking data for PL‑14, broader preclinical hydrogel platform results, and targeting new indications such as epilepsy. More recently, the company reported significant reductions in Der p 1 transfer and completed GMP manufacturing of clinical trial material to support a planned U.S. study. Today’s CRO agreement for ISO 10993 biocompatibility work fits into this sequence of clinical‑trial readiness activities.

Key Terms

contract research organization, gmp, fda, iso 10993, +3 more

7 terms

contract research organization technical

"agreement with a leading global preclinical Contract Research Organization (CRO)"

A contract research organization (CRO) is an outside company hired to run medical and scientific work for drug, device or biotech developers—like an experienced project manager and lab team that companies rent instead of building in-house. Investors care because CROs influence development speed, quality and cost: delays or successes in trials affect client spending, regulatory risk and ultimately revenues for both the sponsor and the CRO.

gmp regulatory

"includes a recent manufacturing of GMP production of clinical trial material"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

fda regulatory

"successful completion of an FDA pre-submission meeting"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

iso 10993 regulatory

"preclinical biocompatibility studies in accordance with ISO 10993 standards"

A family of international standards for testing whether materials and medical devices are safe to touch or put into the human body, covering chemical, biological and toxicological tests. Investors should care because meeting these standards is often required for regulatory approval and market access; think of it as a safety passport that reduces the risk of product recalls, delays, or extra testing that can affect costs and sales timelines.

cytotoxicity medical

"program includes cytotoxicity, sensitization, intracutaneous reactivity"

Cytotoxicity is the ability of a substance to kill or damage living cells. Investors watch cytotoxicity results because they indicate whether a drug or chemical is likely to be effective against targeted cells (for example, cancer cells) and whether it poses safety risks to healthy tissue, which affects clinical success, regulatory approval, and commercial potential—similar to knowing if a powerful weed killer also harms the lawn around the weeds.

intracutaneous reactivity medical

"includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity"

Intracutaneous reactivity is a safety test that measures whether a drug, implant, vaccine or other medical material causes local skin irritation when a small amount is injected just under the skin. Investors should care because a strong local reaction can delay approvals, require extra testing, or lead to warning labels and product changes—like finding out a paint causes a rash before selling it widely, which affects time to market and potential sales.

pyrogenicity medical

"acute systemic toxicity and pyrogenicity assessments"

Pyrogenicity is the tendency of a drug, medical device, or biological product to cause fever or inflammatory reactions in the body, usually by contamination with fever-causing substances called pyrogens (for example bacterial endotoxins). Investors should care because high pyrogenicity can trigger product recalls, regulatory delays, costly additional testing or manufacturing changes, and reputational damage—similar to a food safety problem that forces a factory to halt production and fix cleanliness controls.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.

This agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, which also includes a recent manufacturing of GMP production of clinical trial material, successful completion of an FDA pre-submission meeting, and positive preclinical data demonstrating effective allergen-blocking performance.

Under the agreement, the CRO will conduct a comprehensive package of preclinical biocompatibility studies in accordance with ISO 10993 standards and GLP requirements. The studies are expected to commence in the second quarter of 2026 and represent a key milestone in Polyrizon’s potential regulatory pathway toward initiating clinical trials, which are planned to commence later this year.

The preclinical program includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity assessments, designed to support regulatory submissions and ensure product safety prior to human studies.

“This agreement marks an important step in the advancement of our development program,” said Tomer Izraeli, CEO of Polyrizon. “We believe that engaging a globally recognized preclinical partner strengthens our regulatory strategy and supports our expected timeline toward initiating clinical trials later this year.”

Polyrizon continues to execute its development roadmap as it advances its proprietary nasal medical device technology platform toward clinical validation.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses ongoing efforts to advance its clinical development program and the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What agreement did Polyrizon (PLRZ) announce on March 17, 2026?

Polyrizon signed an agreement with a global preclinical CRO to run biocompatibility studies. According to the company, the CRO will perform ISO 10993 and GLP studies supporting regulatory submissions.

When will Polyrizon (PLRZ) start the preclinical biocompatibility studies?

The studies are expected to commence in Q2 2026. According to the company, this timeline is part of its path toward initiating clinical trials later in 2026.

What specific tests will the CRO perform for Polyrizon (PLRZ)?

The preclinical program includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity and pyrogenicity. According to the company, these assessments follow ISO 10993 and GLP requirements.

How does the CRO agreement affect Polyrizon's clinical trial timeline for PLRZ?

The agreement advances the regulatory pathway and supports planned trials later in 2026. According to the company, the studies are a key milestone before human studies can begin.

Has Polyrizon (PLRZ) completed any other regulatory or manufacturing steps?

Yes. Polyrizon completed GMP production of clinical trial material and an FDA pre‑submission meeting. According to the company, these steps complement the new CRO agreement.

What safety standards will govern Polyrizon's preclinical testing for PLRZ?

Testing will follow ISO 10993 biocompatibility standards and GLP requirements. According to the company, this ensures regulatory‑compliant safety data for future submissions.